CHICAGO--(BUSINESS WIRE)--bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID® molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site (CUP). The results were presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
